IGC Pharma
6 hedge funds and large institutions have $462K invested in IGC Pharma in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.
68% more capital invested
Capital invested by funds: $276K → $462K (+$186K)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more funds holding
Funds holding: 5 → 6 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$11.8K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$6.75K |
| 3 |
VIA
Vantage Investment Advisors
State College,
Pennsylvania
|
+$1.13K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$254 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$31 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$34K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$2K |
IGC Hedge Fund Activity: Q2 2014 in Review
6 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2014, worth a combined $462K — up 68% from $276K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IGC positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $11.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $34K sold.
- 6 institutional investors held IGC Pharma (IGC) as of Q2 2014, up from 5 in Q1 2014.
- Funds reported $462K of IGC Pharma stock for Q2 2014, up 68% quarter-over-quarter.
- 3 funds opened new IGC Pharma positions in Q2 2014 and 2 closed out, a net change of +1 holder.
- The largest IGC Pharma buyer in Q2 2014 was Goldman Sachs, an estimated $11.8K added.
- The largest IGC Pharma seller in Q2 2014 was Citadel Advisors, an estimated $34K sold.
Based on aggregated 13F filings for Q2 2014.